ArticleWorld journal of urology2025
Systematic biopsies of the upper urinary tract: a tool to improve the diagnostic accuracy of ureteroscopy and characterization of upper tract urothelial cancer.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Distal ureterectomy versus radical nephroureterectomy for nonmetastatic distal ureteral urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis of comparative studies.World journal of surgical oncology · 2026Pooled it
- Prognostic value of pathological T stage and independent survival benefit of adjuvant chemotherapy for upper tract urothelial carcinoma: real-world data from a high-volume Vietnamese center.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe use of systematic biopsies (SB) in patients with suspicion of upper tract urothelial carcinoma (UTUC) has not been explored. Our objective is to investigate the safety of SB and its impact on the management of UTUC.
methodsWe included patients who underwent diagnostic ureteroscopy (URS) ± ablation treatment and SB for UTUC at our institution (2015-2022). SB consisted of a minimum of two biopsies in renal pelvis, proximal, medium, and distal ureter. Complications were graded using Clavien-Dindo classification. The impact of SB on oncological outcomes was assessed through Kaplan-Meier curves and Cox regression analysis. Logistic regressions were used to assess predictors of positive SB.
resultsOverall, 50/101 (50%) patients had positive SB. Overall and major complications were 19 (19%) and 4 (4%), respectively. SB detected UTUC in 8/16 (50%) and 18/23 (78%) patients with negative/nondiagnostic and positive target biopsy, respectively. In 8/25 (32%) distal ureteral tumors, SB detected CIS in other upper tract portions. Patients with positive SB were more frequently treated with radical nephroureterectomy (RNU) (2-yr RNU-FS rates 87.7% vs. 53.5%, p < 0.001). SB was an independent predictor of RNU-FS [HR 3.38 (95%CI 1.46-7.80); p = 0.004]. History of CIS [OR 1.26 (95%CI 1.06-1.91), p = 0.04] and tumors ≥ 2 cm [OR 1.32 (95%CI 1.09-1.78), p = 0.04] were independent predictors of SB positivity. Limitations include the single-center, retrospective design of the study.
conclusionsThe integration of SB into the diagnostic workup of UTUC is safe and feasible. It may drive the treatment choice in high-risk patients.
Indexed as
Identifiers
41099868What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.